Dataset from A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00007364
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab
SC) as maintenance treatment in participants with moderately to severely active CD who
achieved clinical response following administration of vedolizumab intravenous (vedolizumab
IV) induction therapy.
创建时间：
2025-10-01
